Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Muscarinic acetylcholine receptor | Starlite/ChEMBL | References |
Rattus norvegicus | Muscarinic acetylcholine receptor M1 | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0295 | 0.5 | 0.5 |
Trichomonas vaginalis | synaptic glycoprotein sc2, putative | 0.0295 | 0.5 | 0.5 |
Plasmodium vivax | polyprenol reductase, putative | 0.0295 | 0.5 | 0.5 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0295 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0295 | 0.5 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0295 | 0.5 | 0.5 |
Leishmania major | 3-oxo-5-alpha-steroid 4-dehydrogenase-like protein | 0.0295 | 0.5 | 0.5 |
Echinococcus multilocularis | synaptic glycoprotein sc2 | 0.0295 | 0.5 | 0.5 |
Toxoplasma gondii | 3-oxo-5-alpha-steroid 4-dehydrogenase | 0.0295 | 0.5 | 0.5 |
Echinococcus multilocularis | 3 oxo 5 alpha steroid 4 dehydrogenase, C terminal | 0.0295 | 0.5 | 0.5 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0295 | 0.5 | 0.5 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0295 | 0.5 | 0.5 |
Toxoplasma gondii | 3-oxo-5-alpha-steroid 4-dehydrogenase | 0.0295 | 0.5 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0295 | 0.5 | 0.5 |
Trypanosoma cruzi | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0295 | 0.5 | 0.5 |
Plasmodium falciparum | polyprenol reductase, putative | 0.0295 | 0.5 | 0.5 |
Entamoeba histolytica | 3-oxo-5-alpha-steroid 4-dehydrogenase domain-containing protein | 0.0295 | 0.5 | 0.5 |
Schistosoma mansoni | synaptic glycoprotein sc2 related | 0.0295 | 0.5 | 0.5 |
Trypanosoma brucei | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0295 | 0.5 | 0.5 |
Giardia lamblia | Synaptic glycoprotein SC2 | 0.0295 | 0.5 | 0.5 |
Onchocerca volvulus | 0.0295 | 0.5 | 0.5 | |
Echinococcus granulosus | synaptic glycoprotein sc2 | 0.0295 | 0.5 | 0.5 |
Plasmodium falciparum | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0295 | 0.5 | 0.5 |
Toxoplasma gondii | 3-oxo-5-alpha-steroid 4-dehydrogenase | 0.0295 | 0.5 | 0.5 |
Echinococcus granulosus | 3 oxo 5 alpha steroid 4 dehydrogenase C terminal | 0.0295 | 0.5 | 0.5 |
Entamoeba histolytica | steroid 5-alpha reductase, putative | 0.0295 | 0.5 | 0.5 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0295 | 0.5 | 0.5 |
Trypanosoma brucei | 3-oxo-5-alpha-steroid 4-dehydrogenase-like, putative | 0.0295 | 0.5 | 0.5 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0295 | 0.5 | 0.5 |
Schistosoma mansoni | synaptic glycoprotein sc2 related | 0.0295 | 0.5 | 0.5 |
Brugia malayi | 3-oxo-5-alpha-steroid 4-dehydrogenase 1 | 0.0295 | 0.5 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0295 | 0.5 | 0.5 |
Trichomonas vaginalis | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative | 0.0295 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0295 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0295 | 0.5 | 0.5 |
Trichomonas vaginalis | synaptic glycoprotein sc2, putative | 0.0295 | 0.5 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0295 | 0.5 | 0.5 |
Entamoeba histolytica | trans-2,3-enoyl-CoA reductase, putative | 0.0295 | 0.5 | 0.5 |
Trichomonas vaginalis | synaptic glycoprotein sc2, putative | 0.0295 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | = 90 nM | In vitro binding affinity for muscarinic receptor by displacing [3H]-quinuclidinyl benzilate binding on rat brain stem homogenate. | ChEMBL. | 7990109 |
Ki (binding) | = 90 nM | In vitro binding affinity for muscarinic receptor by displacing [3H]-quinuclidinyl benzilate binding on rat brain stem homogenate. | ChEMBL. | 7990109 |
Ki (binding) | = 92 nM | In vitro binding affinity for muscarinic receptor by displacing [3H]-oxotremorine-M binding on rat brain homogenate. | ChEMBL. | 7990109 |
Ki (binding) | = 92 nM | In vitro binding affinity for muscarinic receptor by displacing [3H]-oxotremorine-M binding on rat brain homogenate. | ChEMBL. | 7990109 |
Ki (binding) | = 120 nM | In vitro binding affinity for muscarinic M1 receptor by displacing [3H]-Pirenzepine binding on rat brain homogenate. | ChEMBL. | 7990109 |
Ki (binding) | = 120 nM | In vitro binding affinity for muscarinic M1 receptor by displacing [3H]-Pirenzepine binding on rat brain homogenate. | ChEMBL. | 7990109 |
Ki (binding) | = 230 nM | In vitro binding affinity for muscarinic receptor by displacing [3H]-Quinuclidinyl benzilate binding on rat brain homogenate | ChEMBL. | 7990109 |
Ki (binding) | = 230 nM | In vitro binding affinity for muscarinic receptor by displacing [3H]-Quinuclidinyl benzilate binding on rat brain homogenate | ChEMBL. | 7990109 |
Ratio (functional) | = 0.8 | Ratio of binding affinity at [3H]-Quinuclidinyl benzilate binding on rat brain stem homogenate to [3H]-Piperazine binding on rat brain homogenate | ChEMBL. | 7990109 |
Ratio (functional) | = 2.5 | Ratio of binding affinity at [3H]-Quinuclidinyl benzilate binding on rat brain homogenate to [3H]- Oxotremorine-M binding on rat brain homogenate | ChEMBL. | 7990109 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.